Martina Niewerth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Martina Niewerth has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Kirsten Minden
Klinik für Pädiatrie mit SP Pneumologie, Immunologie und Intensivmedizin, Charité Universitätsmedizin Berlin, Berlin, Deutschland
9 shared publications - Kirsten Minden
Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin und Deutsches Rheuma-Forschungszentrum Berlin
8 shared publications - Arnd Heiligenhaus
Department of Ophthalmology and Ophtha-Lab at St. Franziskus Hospital, Münster, Germany
5 shared publications - Jens Klotsche
German Rheumatism Research Center Berlin, Berlin, Germany
5 shared publications - Gerd Horneff
Department of General Paediatrics Asklepios Clinic Sankt Augustin Sankt Augustin Germany
4 shared publications A. Zink
Deutsches Rheumaforschungszentrum Berlin
3 shared publications
Latest Publications
- 8 June 2022
- Published by Springer Nature
- p. 155-165
Assessment-Tools in der pädiatrischen Rheumatologie
- 8 June 2022
- Published by Springer Nature
- p. 155-165
Assessment-Tools in der pädiatrischen Rheumatologie
- Open Access
- 1 October 2019
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 17 (1) , 1-14
Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
Background: JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with significant long-term complications and risk of blindness, even with improved contemporary treatments. The MIWGUC was set up in order to propose specific JIAU activity and response items and to validate their applicability for clinical outcome studies. Methods: The group consists of 8 paediatric rheumatologists and 7 ophthalmologists. A consensus meeting took place on November 2015 in Barcelona (Spain) with the objective of validating the previously proposed measures. The validation process was based on the results of a prospective open, international, multi-centre, cohort study designed to validate the outcome measures proposed by the initial MIWGUC group meeting in 2012. The meeting used the same Delphi and nominal group technique as previously described in the first paper from the MIWGUC group (Arthritis Care Res 64:1365–72, 2012). Patients were included with a diagnosis of JIA, aged less than 18 years, and with active uveitis or an uveitis flare which required treatment with a disease-modifying anti-rheumatic drug. The proposed outcome measures for uveitis were collected by an ophthalmologist and for arthritis by a paediatric rheumatologist. Patient reported outcome measures were also measured. Results: A total of 82 patients were enrolled into the validation cohort. Fifty four percent (n = 44) had persistent oligoarthritis followed by rheumatoid factor negative polyarthritis (n = 15, 18%). The mean uveitis disease duration was 3.3 years (SD 3.0). Bilateral eye involvement was reported in 65 (79.3%) patients. The main findings are that the most significant changes, from baseline to 6 months, are found in the AC activity measures of cells and flare. These measures correlate with the presence of pre-existing structural complications and this has implications for the reporting of trials using a single measure as a primary outcome. We also found that visual analogue scales of disease activity showed significant change when reported by the ophthalmologist, rheumatologist and families. The measures formed three relatively distinct groups. The first group of measures comprised uveitis activity, ocular damage and the ophthalmologists’ VAS. The second comprised patient reported outcomes including disruption to school attendance. The third group consisted of the rheumatologists’ VAS and the joint score. Conclusions: We propose distinctive and clinically significant measures of disease activity, severity and damage for JIAU. This effort is the initial step for developing a comprehensive outcome measures for JIAU, which incorporates the perspectives of rheumatologists, ophthalmologists, patients and families.
- 1 October 2019
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 17 (1) , 1-14
Open AccessProposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
Background: JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with significant long-term complications and risk of blindness, even with improved contemporary treatments. The MIWGUC was set up in order to propose specific JIAU activity and response items and to validate their applicability for clinical outcome studies. Methods: The group consists of 8 paediatric rheumatologists and 7 ophthalmologists. A consensus meeting took place on November 2015 in Barcelona (Spain) with the objective of validating the previously proposed measures. The validation process was based on the results of a prospective open, international, multi-centre, cohort study designed to validate the outcome measures proposed by the initial MIWGUC group meeting in 2012. The meeting used the same Delphi and nominal group technique as previously described in the first paper from the MIWGUC group (Arthritis Care Res 64:1365–72, 2012). Patients were included with a diagnosis of JIA, aged less than 18 years, and with active uveitis or an uveitis flare which required treatment with a disease-modifying anti-rheumatic drug. The proposed outcome measures for uveitis were collected by an ophthalmologist and for arthritis by a paediatric rheumatologist. Patient reported outcome measures were also measured. Results: A total of 82 patients were enrolled into the validation cohort. Fifty four percent (n = 44) had persistent oligoarthritis followed by rheumatoid factor negative polyarthritis (n = 15, 18%). The mean uveitis disease duration was 3.3 years (SD 3.0). Bilateral eye involvement was reported in 65 (79.3%) patients. The main findings are that the most significant changes, from baseline to 6 months, are found in the AC activity measures of cells and flare. These measures correlate with the presence of pre-existing structural complications and this has implications for the reporting of trials using a single measure as a primary outcome. We also found that visual analogue scales of disease activity showed significant change when reported by the ophthalmologist, rheumatologist and families. The measures formed three relatively distinct groups. The first group of measures comprised uveitis activity, ocular damage and the ophthalmologists’ VAS. The second comprised patient reported outcomes including disruption to school attendance. The third group consisted of the rheumatologists’ VAS and the joint score. Conclusions: We propose distinctive and clinically significant measures of disease activity, severity and damage for JIAU. This effort is the initial step for developing a comprehensive outcome measures for JIAU, which incorporates the perspectives of rheumatologists, ophthalmologists, patients and families.
- Open Access
- 11 February 2019
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 17 (1) , 1-10
Participation in school sports among children and adolescents with juvenile idiopathic arthritis in the German National Paediatric Rheumatologic Database, 2000–2015: results from a prospective observational cohort study
Regular school sports can help adolescents achieve the recommended amount of daily physical activity and provide knowledge, attitudes and behavioral skills that are needed in order to adopt and maintain a physically active lifestyle. Furthermore, it reaches all children including those that are at risk for engaging in more sedentary types of behavior. Since adolescents with juvenile idiopathic arthritis (JIA) are less involved in physical and social activities than their healthy peers, the objectives were to (1) estimate the prevalence of participation in school sports among patients with JIA; (2) determine the correlates associated with school sports absenteeism; and (3) investigate whether attendance in school sports has changed in the era of biologics. Data from schoolchildren with JIA recorded in the German National Paediatric Rheumatologic Database (NPRD) in the years 2000 to 2015 were considered for the analyses. Data from the year 2015 were inspected to analyze correlates of school sports absenteeism. Whether school sports participation had changed between 2000 and 2015 was determined using linear mixed models. During the 15-year period, the participation rates in school sports were determined in 23,016 patients. The proportion of patients who participated in school sports almost always steadily increased from 31% in 2000 to 64% in 2015 (β = 0.017, 95% confidence interval (CI) 0.015, 0.020), whereas the exemption rate simultaneously decreased from 44% in 2000 to 16% in 2015 [β = − 0.009, 95% CI -0.011, − 0.007]. In 2015, the data from 5879 patients (mean age 13.1 ± 3.3 years, female 65%, disease duration 5.9 ± 4.0 years, persistent oligoarthritis 37%) were available for evaluation. Full exemption from school sports (in 16.1% of cases) was associated with functional limitations, disease activity and any use of DMARDs, intra-articular glucocorticoid injections or physiotherapy. School sports attendance among children and adolescents with JIA has increased significantly over the past 15 years. Possible explanations include improved functional ability probably due to better treatment options. The integration of patients with child acceptable symptom states who have previously been fully exempted from school sports needs to be addressed in the future.
- 11 February 2019
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 17 (1) , 1-10
Open AccessParticipation in school sports among children and adolescents with juvenile idiopathic arthritis in the German National Paediatric Rheumatologic Database, 2000–2015: results from a prospective observational cohort study
Regular school sports can help adolescents achieve the recommended amount of daily physical activity and provide knowledge, attitudes and behavioral skills that are needed in order to adopt and maintain a physically active lifestyle. Furthermore, it reaches all children including those that are at risk for engaging in more sedentary types of behavior. Since adolescents with juvenile idiopathic arthritis (JIA) are less involved in physical and social activities than their healthy peers, the objectives were to (1) estimate the prevalence of participation in school sports among patients with JIA; (2) determine the correlates associated with school sports absenteeism; and (3) investigate whether attendance in school sports has changed in the era of biologics. Data from schoolchildren with JIA recorded in the German National Paediatric Rheumatologic Database (NPRD) in the years 2000 to 2015 were considered for the analyses. Data from the year 2015 were inspected to analyze correlates of school sports absenteeism. Whether school sports participation had changed between 2000 and 2015 was determined using linear mixed models. During the 15-year period, the participation rates in school sports were determined in 23,016 patients. The proportion of patients who participated in school sports almost always steadily increased from 31% in 2000 to 64% in 2015 (β = 0.017, 95% confidence interval (CI) 0.015, 0.020), whereas the exemption rate simultaneously decreased from 44% in 2000 to 16% in 2015 [β = − 0.009, 95% CI -0.011, − 0.007]. In 2015, the data from 5879 patients (mean age 13.1 ± 3.3 years, female 65%, disease duration 5.9 ± 4.0 years, persistent oligoarthritis 37%) were available for evaluation. Full exemption from school sports (in 16.1% of cases) was associated with functional limitations, disease activity and any use of DMARDs, intra-articular glucocorticoid injections or physiotherapy. School sports attendance among children and adolescents with JIA has increased significantly over the past 15 years. Possible explanations include improved functional ability probably due to better treatment options. The integration of patients with child acceptable symptom states who have previously been fully exempted from school sports needs to be addressed in the future.
- Open Access
- 13 December 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-9
Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort
The objective was to evaluate the 25(OH) vitamin D (25(OH)D) status of patients with juvenile idiopathic arthritis (JIA) and determine whether the 25(OH)D level is associated with disease activity and the course of JIA. Patients ≤ 16 years of age with recently diagnosed JIA (< 12 months) were enrolled in the inception cohort of patients with newly diagnosed JIA (ICON), an ongoing prospective observational, controlled multicenter study started in 2010. Clinical and laboratory parameters were ascertained quarterly during the first year and half-yearly thereafter. Of the 954 enrolled patients, 360 patients with two blood samples taken during the first 2 years after inclusion and with follow up of 3 years were selected. The serum 25(OH)D levels were determined and compared with those of subjects from the general population after matching for age, sex, migration status and the month of blood-drawing. Nearly half of the patients had a deficient 25(OH)D level (< 20 ng/ml) in the first serum sample and a quarter had a deficient level in both samples. Disease activity and the risk of developing JIA-associated uveitis were inversely correlated with the 25(OH)D level (β = − 0.20, 95% CI − 0.37; 0.03, hazard ratio 0.95, 95% CI 0.91; 0.99, respectively). In this study, 25(OH)D deficiency was common and associated with higher disease activity and risk of developing JIA-associated uveitis. Further studies are needed to substantiate these results and determine whether correcting 25(OH)D deficiency is beneficial in JIA.
- 13 December 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-9
Open AccessVitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort
The objective was to evaluate the 25(OH) vitamin D (25(OH)D) status of patients with juvenile idiopathic arthritis (JIA) and determine whether the 25(OH)D level is associated with disease activity and the course of JIA. Patients ≤ 16 years of age with recently diagnosed JIA (< 12 months) were enrolled in the inception cohort of patients with newly diagnosed JIA (ICON), an ongoing prospective observational, controlled multicenter study started in 2010. Clinical and laboratory parameters were ascertained quarterly during the first year and half-yearly thereafter. Of the 954 enrolled patients, 360 patients with two blood samples taken during the first 2 years after inclusion and with follow up of 3 years were selected. The serum 25(OH)D levels were determined and compared with those of subjects from the general population after matching for age, sex, migration status and the month of blood-drawing. Nearly half of the patients had a deficient 25(OH)D level (< 20 ng/ml) in the first serum sample and a quarter had a deficient level in both samples. Disease activity and the risk of developing JIA-associated uveitis were inversely correlated with the 25(OH)D level (β = − 0.20, 95% CI − 0.37; 0.03, hazard ratio 0.95, 95% CI 0.91; 0.99, respectively). In this study, 25(OH)D deficiency was common and associated with higher disease activity and risk of developing JIA-associated uveitis. Further studies are needed to substantiate these results and determine whether correcting 25(OH)D deficiency is beneficial in JIA.
- Open Access
- 30 May 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 106
The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON)
Achieving the best possible health-related quality of life (HRQoL) for a patient is an important treatment goal in juvenile idiopathic arthritis (JIA). We investigated the 36-month trajectories of HRQoL in children with JIA compared with healthy peers and identified the predictors of an unfavorable HRQoL. Patients with a recent JIA diagnosis were enrolled in the German inception cohort study ICON. As a peer group, friends of patients of the same age and sex were asked to cooperate. Children were prospectively followed and regularly questioned about their HRQoL using the Pediatric Quality of Life Inventory 4.0 (PedsQL). Disease activity was assessed by the clinical Juvenile Arthritis Disease Activity Score (cJADAS-10), and the burden of the child’s chronic illness on their family was assessed by the Family Burden Questionnaire (FaBel). Linear mixed models were used to compare the HRQoL of the patients and their peers. Associations between the health status of a patient at enrollment and an unfavorable HRQoL (PedsQL total < 79.3) at their 3-year follow-up (FU) were analyzed by logistic regression. Data from 953 patients (median symptom duration 6 months, mean age 7.9 years) and 491 healthy peers (aged 8.4 years) were analyzed. During 3 years of FU, the disease activity and HRQoL of the patients improved significantly (cJADAS-10 from 9.8 (6.2) to 2.7 (3.6) and PedsQL total score from 71.7 (18.2) to 87.3 (13.9)). While the HRQoL of the patients varied among the several JIA categories at the time of enrollment, no significant differences were found at the 3-year FU. After 36 months, the HRQoL of the patients had largely converged with that of their healthy peers. JIA patients had a psychosocial health status comparable with their healthy peers, whereas a small significant mean difference remained in physical health (5.8, 95% confidence interval (CI) 4.1–7.6). Up to the 36-month FU, three-quarters of JIA patients attained a favorable HRQoL (PedsQL ≥ 79.3) which was achieved by 90% of the peers. A higher family burden, higher pain level, and lower well-being at enrollment were associated with an unfavorable HRQoL. Under current therapeutic conditions, an HRQoL corresponding with that of healthy children is a realistic treatment goal in JIA.
- 30 May 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 106
Open AccessThe majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON)
Achieving the best possible health-related quality of life (HRQoL) for a patient is an important treatment goal in juvenile idiopathic arthritis (JIA). We investigated the 36-month trajectories of HRQoL in children with JIA compared with healthy peers and identified the predictors of an unfavorable HRQoL. Patients with a recent JIA diagnosis were enrolled in the German inception cohort study ICON. As a peer group, friends of patients of the same age and sex were asked to cooperate. Children were prospectively followed and regularly questioned about their HRQoL using the Pediatric Quality of Life Inventory 4.0 (PedsQL). Disease activity was assessed by the clinical Juvenile Arthritis Disease Activity Score (cJADAS-10), and the burden of the child’s chronic illness on their family was assessed by the Family Burden Questionnaire (FaBel). Linear mixed models were used to compare the HRQoL of the patients and their peers. Associations between the health status of a patient at enrollment and an unfavorable HRQoL (PedsQL total < 79.3) at their 3-year follow-up (FU) were analyzed by logistic regression. Data from 953 patients (median symptom duration 6 months, mean age 7.9 years) and 491 healthy peers (aged 8.4 years) were analyzed. During 3 years of FU, the disease activity and HRQoL of the patients improved significantly (cJADAS-10 from 9.8 (6.2) to 2.7 (3.6) and PedsQL total score from 71.7 (18.2) to 87.3 (13.9)). While the HRQoL of the patients varied among the several JIA categories at the time of enrollment, no significant differences were found at the 3-year FU. After 36 months, the HRQoL of the patients had largely converged with that of their healthy peers. JIA patients had a psychosocial health status comparable with their healthy peers, whereas a small significant mean difference remained in physical health (5.8, 95% confidence interval (CI) 4.1–7.6). Up to the 36-month FU, three-quarters of JIA patients attained a favorable HRQoL (PedsQL ≥ 79.3) which was achieved by 90% of the peers. A higher family burden, higher pain level, and lower well-being at enrollment were associated with an unfavorable HRQoL. Under current therapeutic conditions, an HRQoL corresponding with that of healthy children is a realistic treatment goal in JIA.
- Open Access
- 19 April 2017
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 15 (1) , 1-9
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
To characterize the existing national and multi-national registries and cohort studies in juvenile idiopathic arthritis (JIA) and identify differences as well as areas of potential future collaboration. We surveyed investigators from North America, Europe, and Australia about existing JIA cohort studies and registries. We excluded cross-sectional studies. We captured information about study design, duration, location, inclusion criteria, data elements and collection methods. We received survey results from 18 studies, including 11 national and 7 multi-national studies representing 37 countries in total. Study designs included inception cohorts, prevalent disease cohorts, and new treatment cohorts (several of which contribute to pharmacosurveillance activities). Despite numerous differences, the data elements collected across the studies was quite similar, with most studies collecting at least 5 of the 6 American College of Rheumatology core set variables and the data needed to calculate the 3-variable clinical juvenile disease activity score. Most studies were collecting medication initiation and discontinuation dates and were attempting to capture serious adverse events. There is a wide-range of large, ongoing JIA registries and cohort studies around the world. Our survey results indicate significant potential for future collaborative work using data from different studies and both combined and comparative analyses.
- 19 April 2017
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 15 (1) , 1-9
Open AccessA survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
To characterize the existing national and multi-national registries and cohort studies in juvenile idiopathic arthritis (JIA) and identify differences as well as areas of potential future collaboration. We surveyed investigators from North America, Europe, and Australia about existing JIA cohort studies and registries. We excluded cross-sectional studies. We captured information about study design, duration, location, inclusion criteria, data elements and collection methods. We received survey results from 18 studies, including 11 national and 7 multi-national studies representing 37 countries in total. Study designs included inception cohorts, prevalent disease cohorts, and new treatment cohorts (several of which contribute to pharmacosurveillance activities). Despite numerous differences, the data elements collected across the studies was quite similar, with most studies collecting at least 5 of the 6 American College of Rheumatology core set variables and the data needed to calculate the 3-variable clinical juvenile disease activity score. Most studies were collecting medication initiation and discontinuation dates and were attempting to capture serious adverse events. There is a wide-range of large, ongoing JIA registries and cohort studies around the world. Our survey results indicate significant potential for future collaborative work using data from different studies and both combined and comparative analyses.
- 30 October 2015
- Vol. 33 (6) , 936-44
Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis:data from a cross-sectional analysis of a prospective nationwide study.
To analyse the nationwide prevalence of uveitis in JIA and its complications over a whole decade. We conducted a prospective, observational and cross-sectional study including all JIA patients from a National Paediatric Rheumatological Database (NPRD) with a uveitis add-on module in Germany (2002-2013). Temporal changes in uveitis prevalence, related secondary complications and anti-inflammatory medication were evaluated. A total of 60 centres including 18,555 JIA patients (mean 3,863 patients/year, SD=837) were documented in the NPRD between 2002 and 2013. The mean age of the patients was 11.4 ± 4.6 years, their mean disease duration 4.4 ± 3.7 years. Among them, 66.9% were female and 51.7% ANA positive. Patients' mean age at arthritis onset was 6.9 ± 4.5 years. Treatment rates with synthetic and biological DMARDs increased during the observation period (sDMARD: 39.8% to 47.2%, bDMARD: 3.3% to 21.8%). Uveitis prevalence decreased significantly from 2002 to 2013 (13.0% to 11.6%, OR = 0.98, p=0.015). The prevalence of secondary uveitis complications also decreased significantly between 2002 and 2013 (33.6% to 23.9%, OR=0.94, p<0.001). Among the complications, the most common ones were posterior synechiae, cataract and band keratopathy. A significant increase in achieving uveitis inactivity was observed at 30.6% in 2002 and 65.3% in 2013 (OR=1.15, p<0.001). Uveitis prevalence and complications significantly decreased between 2002 and 2013. This may be associated with a more frequent use of DMARDs.
- 30 October 2015
- Vol. 33 (6) , 936-44
Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis:data from a cross-sectional analysis of a prospective nationwide study.
To analyse the nationwide prevalence of uveitis in JIA and its complications over a whole decade. We conducted a prospective, observational and cross-sectional study including all JIA patients from a National Paediatric Rheumatological Database (NPRD) with a uveitis add-on module in Germany (2002-2013). Temporal changes in uveitis prevalence, related secondary complications and anti-inflammatory medication were evaluated. A total of 60 centres including 18,555 JIA patients (mean 3,863 patients/year, SD=837) were documented in the NPRD between 2002 and 2013. The mean age of the patients was 11.4 ± 4.6 years, their mean disease duration 4.4 ± 3.7 years. Among them, 66.9% were female and 51.7% ANA positive. Patients' mean age at arthritis onset was 6.9 ± 4.5 years. Treatment rates with synthetic and biological DMARDs increased during the observation period (sDMARD: 39.8% to 47.2%, bDMARD: 3.3% to 21.8%). Uveitis prevalence decreased significantly from 2002 to 2013 (13.0% to 11.6%, OR = 0.98, p=0.015). The prevalence of secondary uveitis complications also decreased significantly between 2002 and 2013 (33.6% to 23.9%, OR=0.94, p<0.001). Among the complications, the most common ones were posterior synechiae, cataract and band keratopathy. A significant increase in achieving uveitis inactivity was observed at 30.6% in 2002 and 65.3% in 2013 (OR=1.15, p<0.001). Uveitis prevalence and complications significantly decreased between 2002 and 2013. This may be associated with a more frequent use of DMARDs.
- 22 July 2015
- Published by Georg Thieme Verlag KG in Aktuelle Rheumatologie
- Vol. 40 (04) , 268-274
Transition – ein erfolgreiches Konzept in der Behandlung der JIA
Die häufigste entzündlich-rheumatische Erkrankung des Kindes- und Jugendalters, die juvenile idiopathische Arthritis (JIA), bleibt oft bis ins Erwachsenenalter aktiv bzw. medikamentös behandlungsbedürftig. Bei etwa der Hälfte der Patienten besteht deshalb ein fachspezifischer Betreuungsbedarf über das Jugendalter hinaus. Die meisten der weiter betreuungsbedürftigen Patienten haben eine polyartikuläre JIA oder Spondylarthritis und weisen mit einer asymmetrischen Oligoarthritis, kaum erhöhten Entzündungsparametern und einer asymptomatischen Augenentzündung für chronische Arthritiden im Erwachsenenalter eher untypische artikuläre und extraartikuläre Manifestationen auf. Für die Betroffenen stellt der Übergang in das Erwachsenenalter oft einen schwierigen Prozess dar. Neben der Absolvierung der normalen Entwicklungsaufgaben haben die jungen Rheumatiker nach Verlassen der pädiatrischen Obhut zeitnah einen internistischen Rheumatologen aufzusuchen. Letzteres gelingt in etwa einem Drittel der Fälle nicht. Von denjenigen, die die internistische Rheumatologie erreichen, kommt ein beträchtlicher Teil mit der neuen Betreuungssituation nicht zurecht und ist dementsprechend unzufrieden. Mit speziellen Maßnahmen und Programmen versucht man deshalb, die Betroffenen entsprechend ihrer individuellen medizinischen, psychosozialen und Bildungs-/beruflichen Bedürfnisse zu unterstützen und eine kontinuierliche medizinische Versorgung zu organisieren. Die hierfür erforderlichen und über die Regelversorgung hinausgehenden Versorgungsleistungen werden bisher allerdings nicht flächendeckend angeboten, wenngleich es ausreichend Evidenz für deren Notwendigkeit gibt. Strukturelle und psychosoziale Barrieren stehen dem entgegen. Transition erfordert eine Umorganisation des Praxisalltags, die u. a. ausreichend lange Konsultationszeiten, eine altersangepasste Gesprächsführung, das Adressieren altersspezifischer Themen und eine gute Kooperation zwischen Pädiater und Internist einschließt. Bedarf besteht, die Wirksamkeit von Transitionsmaßnahmen zu belegen. Damit könnte eine Voraussetzung für die Anerkennung von Transition als Leistung der Regelversorgung geschaffen werden. The most common chronic inflammatory rheumatic disease of childhood and adolescence, juvenile idiopathic arthritis (JIA), often persists into adulthood. About half of the patients are in need of rheumatological care beyond adolescence. Most of these patients have polyarticular JIA or spondylarthritis and present with rather unusual articular and extra-articular manifestations, such as asymmetric oligoarthritis, hardly elevated inflammatory laboratory parameters and asymptomatic uveitis, to adult rheumatologists. For young people with JIA, the transition to adulthood is a challenging process. The patients have to complete the normal developmental tasks, but have also to manage the transfer to adult care. The latter works in only 2 of 3 cases. Of those young people who reach adult rheumatology care, a significant proportion is not able to cope with the new setting of care and is accordingly unsatisfied. Therefore, specific measures and programmes have been established to support the young people in the transition process according to their individual medical, psychosocial and educational/vocational needs and to organise a continuous medical care. However, the implementation of such youth-friendly services including transitional care has been frustratingly slow. Many structural and psychosocial barriers do exist and prevent the widespread implementation of health transition supports. Transition is resource consuming. It requires a reorganisation of workstreams to accommodate a clear, well-documented transitional pathway, including among other things, sufficiently long consultation times, an age-appropriate communication, addressing of age-specific topics and a close cooperation between paediatric and adult rheumatologists. There is a need to evaluate the effectiveness of such measures. That could be a precondition to recognise transition services as part of regular health care.
- 22 July 2015
- Published by Georg Thieme Verlag KG in Aktuelle Rheumatologie
- Vol. 40 (04) , 268-274
Transition – ein erfolgreiches Konzept in der Behandlung der JIA
Die häufigste entzündlich-rheumatische Erkrankung des Kindes- und Jugendalters, die juvenile idiopathische Arthritis (JIA), bleibt oft bis ins Erwachsenenalter aktiv bzw. medikamentös behandlungsbedürftig. Bei etwa der Hälfte der Patienten besteht deshalb ein fachspezifischer Betreuungsbedarf über das Jugendalter hinaus. Die meisten der weiter betreuungsbedürftigen Patienten haben eine polyartikuläre JIA oder Spondylarthritis und weisen mit einer asymmetrischen Oligoarthritis, kaum erhöhten Entzündungsparametern und einer asymptomatischen Augenentzündung für chronische Arthritiden im Erwachsenenalter eher untypische artikuläre und extraartikuläre Manifestationen auf. Für die Betroffenen stellt der Übergang in das Erwachsenenalter oft einen schwierigen Prozess dar. Neben der Absolvierung der normalen Entwicklungsaufgaben haben die jungen Rheumatiker nach Verlassen der pädiatrischen Obhut zeitnah einen internistischen Rheumatologen aufzusuchen. Letzteres gelingt in etwa einem Drittel der Fälle nicht. Von denjenigen, die die internistische Rheumatologie erreichen, kommt ein beträchtlicher Teil mit der neuen Betreuungssituation nicht zurecht und ist dementsprechend unzufrieden. Mit speziellen Maßnahmen und Programmen versucht man deshalb, die Betroffenen entsprechend ihrer individuellen medizinischen, psychosozialen und Bildungs-/beruflichen Bedürfnisse zu unterstützen und eine kontinuierliche medizinische Versorgung zu organisieren. Die hierfür erforderlichen und über die Regelversorgung hinausgehenden Versorgungsleistungen werden bisher allerdings nicht flächendeckend angeboten, wenngleich es ausreichend Evidenz für deren Notwendigkeit gibt. Strukturelle und psychosoziale Barrieren stehen dem entgegen. Transition erfordert eine Umorganisation des Praxisalltags, die u. a. ausreichend lange Konsultationszeiten, eine altersangepasste Gesprächsführung, das Adressieren altersspezifischer Themen und eine gute Kooperation zwischen Pädiater und Internist einschließt. Bedarf besteht, die Wirksamkeit von Transitionsmaßnahmen zu belegen. Damit könnte eine Voraussetzung für die Anerkennung von Transition als Leistung der Regelversorgung geschaffen werden. The most common chronic inflammatory rheumatic disease of childhood and adolescence, juvenile idiopathic arthritis (JIA), often persists into adulthood. About half of the patients are in need of rheumatological care beyond adolescence. Most of these patients have polyarticular JIA or spondylarthritis and present with rather unusual articular and extra-articular manifestations, such as asymmetric oligoarthritis, hardly elevated inflammatory laboratory parameters and asymptomatic uveitis, to adult rheumatologists. For young people with JIA, the transition to adulthood is a challenging process. The patients have to complete the normal developmental tasks, but have also to manage the transfer to adult care. The latter works in only 2 of 3 cases. Of those young people who reach adult rheumatology care, a significant proportion is not able to cope with the new setting of care and is accordingly unsatisfied. Therefore, specific measures and programmes have been established to support the young people in the transition process according to their individual medical, psychosocial and educational/vocational needs and to organise a continuous medical care. However, the implementation of such youth-friendly services including transitional care has been frustratingly slow. Many structural and psychosocial barriers do exist and prevent the widespread implementation of health transition supports. Transition is resource consuming. It requires a reorganisation of workstreams to accommodate a clear, well-documented transitional pathway, including among other things, sufficiently long consultation times, an age-appropriate communication, addressing of age-specific topics and a close cooperation between paediatric and adult rheumatologists. There is a need to evaluate the effectiveness of such measures. That could be a precondition to recognise transition services as part of regular health care.
- 7 August 2014
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 73 (6) , 532-540
Biologikatherapie der juvenilen idiopathische Arthritis im jungen Erwachsenenalter
- 7 August 2014
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 73 (6) , 532-540
Biologikatherapie der juvenilen idiopathische Arthritis im jungen Erwachsenenalter